Samsung Biologics

207940 · KOSPI · Health Care · LARGE CAP

[Amended] Material event report (equity acquisition)

M&A([Amended] Material event report (equity acquisition))· FILED 2026-10-16· RCEPT 20261016000163

About this filing

A decision to buy or sell a business, a major asset or shares in another company, with the counterparty and price.

Why companies file it: Large acquisitions and disposals relative to the company's size are mandatory disclosures.

A full English translation of this filing is not available yet. The original (in Korean) is linked below.

Filed2026-10-16, [Amended] Material event report (equity acquisition)
SourceDART rcept 20261016000163 → open original filing

Versions of this filing

  1. 2026-07-20Original
  2. 2026-08-28Amendment 1
  3. 2026-10-16Amendment 2 (this page)

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-10-16 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).